Category: Clinical Lung Cancer

Association of Operability with Post-Treatment Mortality in Early-Stage Non-Small Cell Lung Cancer

We evaluated the association of operability status with early post-treatment mortality among patients with early-stage non-small cell lung cancer undergoing stereotactic body radiotherapy. In this cohort study of 80,108 patients from a large US cancer dataset, operable patients undergoing stereotactic body radiotherapy experienced <1% risk of mortality through 90 days post-treatment, significantly lower than corresponding rates observed among their inoperable counterparts. These findings imply that non-randomized comparisons of surgical versus non-surgical approaches for early-stage non-small cell lung cancer are vulnerable to confounding by operability and should be interpreted with caution.

Platinum re-exposure as a non-small cell lung cancer (NSCLC) treatment strategy in the age of immunotherapy

Effective treatment strategies after immunotherapy are greatly needed in NSCLC. The time off platinum chemotherapy (platinum-free-interval) is one predictor used to select patients for platinum re-exposure in other malignancies, but is not known in NSCLC. We analyzed a retrospective cohort of 751 patients who underwent this approach and did not find that the platinum-free-interval predicted better outcomes after platinum re-exposure.

Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy

Non-small cell lung cancer (NSCLC) accounts for around 85% of all lung cancers and more than half of the patients with NSCLC have metastatic disease at the time of diagnosis1. The current first-line standard of care for patients with metastatic NSCLC lacking driver mutations is immune-checkpoint inhibitors (ICIs) alone or combined with concurrent chemotherapy2-4. ICIs are highly potent anticancer agents which alleviate the downregulation of T cell function and can restore the immune system to kill cancer cells by blocking the interaction between checkpoint proteins and their ligands5.

Safety and efficacy of extended interval dosing for immune checkpoint inhibitors in non-small cell lung cancer during the COVID-19 pandemic

Extended interval (EI) dosing for immune checkpoint inhibitor (ICI) mono- or consolidation therapy initiated due to the COVID-19 pandemic led to a significant reduction in ICI-related site visits for patients with stage III and IV non-small cell lung cancer (NSCLC). Here we report the safety and efficacy compared to standard dose (SD) schedules.

Molecular characteristics of the uncommon EGFR exon 21 T854A mutation and response to osimertinib in patients with non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is one of the most common causes of cancer death worldwide. Understanding the genetic diversity of NSCLCs has led to the development of molecularly targeted interventions. In particular, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have become a standard therapy for advanced NSCLC. First-generation EGFR-TKIs have been widely adopted against common EGFR mutations, including mutations in exon 21 and insertions or deletions in exon 19.

Enable Notifications    OK No thanks